Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy

Table 4

Reproductive Health Consensus Target Product Profile for MPT Vaccines.

Parameter	Optimally preferred
Indication and mechanism	HSV, HIV, HPV; Systemic and mucosal protective concentrations of neutralizing antibodies (and cell-mediated immunity)
Target population	Women/girls: developed and developing regions
Immunogen, adjuvant, and delivery modes	Well-characterized immunogens (but range of adjuvants and delivery modes
User-action	Pharmacy or self-administered boosts
Boost schedule	Mucosal boost schedule uncertain
Typical use efficacy	HSV (70–90%); HIV (70–90%); HPV (>95%)
Side effect profile	Minimal
Additional benefits	Versatile production platform
Shelf life	Years
Storage needs	No cold chain required
Price	$1/dose
Infrastructure	Pharmacy